Our prior work demonstrates that treatment of HPV− HNSCC cell lines with the combination of an IGF1R inhibitor, BMS754807, and a Src family kinase inhibitor, dasatinib, induces synergistic cytotoxicity5. This evidence concerns the gene IGF1R and head and neck squamous cell carcinoma.